<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>Insight数据库 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-10-29T23:20:30+08:00</updated>
  <subtitle>丁香园 Insight 数据库（db.dxy.cn），拥有申报、临床、上市、药企等 10 大核心数据。致力于分享医药行业政策解读、药企大事和药品申报情报等</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>刚刚！14 个仿制药过评，3 个注射剂，来自天晴、豪森、科伦……</title>
    <updated>2020-10-29T16:44:55+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-29:/s/6xB6wv3tdlveQks9N7-s5g</id>
    <link href="https://mp.weixin.qq.com/s/6xB6wv3tdlveQks9N7-s5g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>28 亿重磅品种！「恩曲他滨替诺福韦片」第二家获批</title>
    <updated>2020-10-29T16:44:55+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-29:/s/YGmRkxB4joXymJkY_4R_Iw</id>
    <link href="https://mp.weixin.qq.com/s/YGmRkxB4joXymJkY_4R_Iw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>豪森药业「沙格列汀片」获批上市，国产第三家</title>
    <updated>2020-10-29T16:44:55+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-29:/s/7YseLRXzu2SYsTvDRMnRVQ</id>
    <link href="https://mp.weixin.qq.com/s/7YseLRXzu2SYsTvDRMnRVQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>7 个新药列入第三批临床急需境外新药名单！已累计 73 个</title>
    <updated>2020-10-29T16:44:55+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-29:/s/QHcg8OL7LTq4zbm2y8tBcg</id>
    <link href="https://mp.weixin.qq.com/s/QHcg8OL7LTq4zbm2y8tBcg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>罗氏 T+A 免疫联合治疗在国内获批，用于肝细胞癌</title>
    <updated>2020-10-29T16:44:55+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-29:/s/PdRfoznpwtGRQV3jO_I3Eg</id>
    <link href="https://mp.weixin.qq.com/s/PdRfoznpwtGRQV3jO_I3Eg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020药品研发质量管理体系建立、实施及研发数据可靠性</title>
    <updated>2020-10-29T16:44:55+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-29:/s/Yngi35oCi5rYxUJP_bdu1g</id>
    <link href="https://mp.weixin.qq.com/s/Yngi35oCi5rYxUJP_bdu1g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>一致性评价，这 21 家药企开始了（附名单）</title>
    <updated>2020-10-28T17:15:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-28:/s/u9MotclQU0fPedUqtKBEGQ</id>
    <link href="https://mp.weixin.qq.com/s/u9MotclQU0fPedUqtKBEGQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>信迪利单抗三季度销售破 6 亿，信达生物 2020 喜讯不断</title>
    <updated>2020-10-28T17:15:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-28:/s/u6VXdxFwvrwIEWbIq3VhVw</id>
    <link href="https://mp.weixin.qq.com/s/u6VXdxFwvrwIEWbIq3VhVw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>贝达药业三季度扣非净利润同比增长 21.20%，埃克替尼继续放量</title>
    <updated>2020-10-28T17:15:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-28:/s/mkA9ZDOTp2hTzMZ-Wki7fg</id>
    <link href="https://mp.weixin.qq.com/s/mkA9ZDOTp2hTzMZ-Wki7fg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>恒瑞医药「注射用 HR17020」启动临床</title>
    <updated>2020-10-28T17:15:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-28:/s/4DwlcmDzKpaoDubr0GpAhw</id>
    <link href="https://mp.weixin.qq.com/s/4DwlcmDzKpaoDubr0GpAhw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>热门靶点 TIGIT，百济再报三项临床，信达、君实、复宏汉霖均在布局</title>
    <updated>2020-10-27T17:33:54+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-27:/s/kftv1iemQPJvZ6l1u-PF_g</id>
    <link href="https://mp.weixin.qq.com/s/kftv1iemQPJvZ6l1u-PF_g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>剧透！Insight 数据库携海量豪礼亮相 DIA 年会</title>
    <updated>2020-10-27T17:33:54+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-27:/s/OsY_RXHVnxoKfXzTdx6M5Q</id>
    <link href="https://mp.weixin.qq.com/s/OsY_RXHVnxoKfXzTdx6M5Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>13 亿美元！基石药业 PD-L1/PD-1 单抗与 EQRx 达成独家授权协议</title>
    <updated>2020-10-27T17:33:54+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-27:/s/_yO6LPrJen8Gv65XuyJmUg</id>
    <link href="https://mp.weixin.qq.com/s/_yO6LPrJen8Gv65XuyJmUg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>正大天晴/康方生物 PD-1 三线治疗转移性鼻咽癌获 FDA 快速审批通道资格</title>
    <updated>2020-10-27T17:33:54+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-27:/s/csAsEq3fv5289Q8rjmgqWQ</id>
    <link href="https://mp.weixin.qq.com/s/csAsEq3fv5289Q8rjmgqWQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>依那西普价格战硝烟再起，三生、海正接连降价</title>
    <updated>2020-10-27T17:33:54+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-27:/s/1hpyGxRbd0TVabZ78i0waA</id>
    <link href="https://mp.weixin.qq.com/s/1hpyGxRbd0TVabZ78i0waA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>研发管线迎收获期，智飞生物重估价值？</title>
    <updated>2020-10-26T17:56:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-26:/s/mHdyR2Lt6jri9SR_57_B6A</id>
    <link href="https://mp.weixin.qq.com/s/mHdyR2Lt6jri9SR_57_B6A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>刚刚，9 款仿制药通过一致性评价，3 款为首家，3 款为第二家</title>
    <updated>2020-10-26T17:56:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-26:/s/cVvlpxriCBtDaoD_XADNxg</id>
    <link href="https://mp.weixin.qq.com/s/cVvlpxriCBtDaoD_XADNxg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>恒瑞 JAK1 抑制剂 II 期临床达到主要研究终点，将启动 III 期临床</title>
    <updated>2020-10-26T17:56:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-26:/s/o6N70EB6vMH_umxExkK56g</id>
    <link href="https://mp.weixin.qq.com/s/o6N70EB6vMH_umxExkK56g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>发力双抗！信达生物 LAG-3/PD-L1 双抗获批临床</title>
    <updated>2020-10-26T17:56:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-26:/s/JlrnF_8FUi7CqooVSj6DIw</id>
    <link href="https://mp.weixin.qq.com/s/JlrnF_8FUi7CqooVSj6DIw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>进军百亿抗纤维化领域！北京泰德 1 类新药 TDI01 获批临床</title>
    <updated>2020-10-26T17:56:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-26:/s/fJs_W_iwB3takVW9BEYX1w</id>
    <link href="https://mp.weixin.qq.com/s/fJs_W_iwB3takVW9BEYX1w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>